

Hanny Al-Samkari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/562452/publications.pdf>

Version: 2024-02-01

120
papers

3,865
citations

212478

28
h-index

162838

57
g-index

120
all docs

120
docs citations

120
times ranked

5467
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. <i>Platelets</i> , 2022, 33, 66-72.	1.1	18
2	Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. <i>Platelets</i> , 2022, 33, 257-264.	1.1	21
3	Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. <i>Angiogenesis</i> , 2022, 25, 87-97.	3.7	20
4	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. <i>Blood Advances</i> , 2022, 6, 1844-1853.	2.5	12
5	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. <i>Blood</i> , 2022, 139, 1564-1574.	0.6	55
6	Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. <i>Neuro-Oncology</i> , 2022, 24, 964-973.	0.6	6
7	Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 708-711.	1.0	3
8	Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia. <i>Drugs of Today</i> , 2022, 58, 105-116.	0.7	1
9	Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. <i>British Journal of Haematology</i> , 2022, 197, 359-366.	1.2	31
10	Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 514-528.	1.5	11
11	Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e179-e189.	2.2	23
12	A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1077-1088.	1.9	16
13	Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29447.	0.8	6
14	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. <i>New England Journal of Medicine</i> , 2022, 386, 1432-1442.	13.9	42
15	Doxycycline for bleeding in hereditary hemorrhagic telangiectasia: When low-changing fruit meets inconvenient data. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1067-1069.	1.9	0
16	The case for classical haematology: the impact of a name and the future of a field. <i>Lancet Haematology</i> , 2022, 9, e455-e459.	2.2	3
17	Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. <i>Cancer</i> , 2022, 128, 3224-3232.	2.0	12
18	An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 783-791.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 255-259.	1.0	5
20	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. <i>Haematologica</i> , 2021, 106, 2161-2169.	1.7	64
21	The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. <i>British Journal of Haematology</i> , 2021, 192, 1092-1096.	1.2	15
22	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. <i>Haematologica</i> , 2021, 106, 1148-1157.	1.7	49
23	An Eltrombopag Red (Plasma) Alert. <i>Acta Haematologica</i> , 2021, 144, 227-228.	0.7	2
24	Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. <i>Blood</i> , 2021, 137, 888-895.	0.6	45
25	New therapeutic horizons in Wiskott-Aldrich syndrome. <i>British Journal of Haematology</i> , 2021, 192, 231-232.	1.2	0
26	Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. <i>Haemophilia</i> , 2021, 27, e270-e273.	1.0	2
27	An evaluation of avatrombopag for the treatment of thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 273-280.	0.9	19
28	Comorbidities and complications in adults with pyruvate kinase deficiency. <i>European Journal of Haematology</i> , 2021, 106, 484-492.	1.1	17
29	d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2021, 49, e500-e511.	0.4	35
30	Recognition of thrombotic risk of thrombocytosis in iron deficiency. <i>Haematologica</i> , 2021, 106, 661-663.	1.7	10
31	Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1613.	3.8	19
32	Tissue Plasminogen Activator in Critically Ill Adults with COVID-19. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1917-1921.	1.5	11
33	Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1852-1863.	1.9	17
34	Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. <i>Expert Review of Hematology</i> , 2021, 14, 437-448.	1.0	29
35	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 622-632.	2.0	89
36	Severe babesiosis with associated splenic infarcts and asplenia. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 597-599.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2348-2354.	1.9	7
38	Giving hereditary haemorrhagic telangiectasia the attention it deserves. <i>Lancet Haematology</i> , 2021, 8, e472-e474.	2.2	5
39	Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 653-664.	0.7	25
40	Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. <i>JAMA Network Open</i> , 2021, 4, e2119812.	2.8	9
41	Response to rituximab in children and adults with immune thrombocytopenia (ITP). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12587.	1.0	4
42	Recognition and management of vascular lesions in von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2122-2124.	1.9	0
43	Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome. <i>Blood Advances</i> , 2021, 5, 3850-3854.	2.5	9
44	Severe autoimmune hemolytic anemia following receipt of SARS-CoV-2 mRNA vaccine. <i>Transfusion</i> , 2021, 61, 3267-3271.	0.8	29
45	Predictors of mortality and outcomes of liver transplant in spur cell hemolytic anemia. <i>American Journal of Hematology</i> , 2021, 96, 1611-1620.	2.0	4
46	Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report. <i>Annals of Internal Medicine</i> , 2021, 174, 1632-1633.	2.0	8
47	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, 1563-1568.	2.0	6
48	TPO versus TPO: the good, the bad, and the to be determined. <i>British Journal of Haematology</i> , 2021, 195, 653-654.	1.2	0
49	Hospitalization As a Risk Factor for Bleeding: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study. <i>Blood</i> , 2021, 138, 1915-1915.	0.6	0
50	Venous and Arterial Thrombosis Following Abemaciclib Therapy for Metastatic Breast Cancer. <i>Blood</i> , 2021, 138, 4063-4063.	0.6	2
51	Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia. <i>Blood</i> , 2021, 138, 584-584.	0.6	0
52	Predictors of Mortality and Outcomes of Liver Transplant in Spur Cell Hemolytic Anemia. <i>Blood</i> , 2021, 138, 1995-1995.	0.6	0
53	Characterization and Prognosis of Temozolomide-Induced Aplastic Anemia. <i>Blood</i> , 2021, 138, 2193-2193.	0.6	1
54	Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study. <i>Blood</i> , 2021, 138, 1015-1015.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 586-586.	0.6	1
56	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. <i>Blood</i> , 2021, 138, 848-848.	0.6	1
57	Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110660.	1.1	31
58	Platelet clump visible to the naked eye in type 2B von Willebrand disease. <i>Blood</i> , 2021, 138, 2742-2742.	0.6	0
59	Cancer-associated thrombosis: Where do we stand?. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e73.	0.6	4
60	The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. <i>European Journal of Haematology</i> , 2020, 104, 79-87.	1.1	112
61	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 275-288.	1.5	49
62	Striving for full disclosure—An intergenerational challenge. <i>Cancer</i> , 2020, 126, 1150-1151.	2.0	10
63	Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 807-812.	1.0	25
64	Cancer and thrombosis: new insights to an old problem. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 6S8-6S16.	0.1	22
65	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. <i>Annals of Internal Medicine</i> , 2020, 173, 989-1001.	2.0	244
66	Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients. <i>Cancers</i> , 2020, 12, 1958.	1.7	21
67	Characterization of the severe phenotype of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020, 95, E281.	2.0	8
68	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (<sc>COVID</sc>—19). <i>American Journal of Hematology</i> , 2020, 95, 1479-1485.	2.0	24
69	A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1340-1342.	1.0	5
70	An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. <i>Haemophilia</i> , 2020, 26, 1038-1045.	1.0	19
71	The role of romiplostim for pediatric patients with immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091299.	1.1	19
72	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> , 2020, 136, 489-500.	0.6	1,021

#	ARTICLE	IF	CITATIONS
73	How to focus our efforts in improving prognostic disclosure in oncology. <i>Cancer</i> , 2020, 126, 2716-2717.	2.0	3
74	ABO phenotype and death in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e204-e208.	1.2	62
75	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. <i>American Journal of Hematology</i> , 2020, 95, 1180-1186.	2.0	26
76	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00118.	1.3	3
77	Partial Suture Fusion in Nonsyndromic Single-Suture Craniosynostosis. <i>Cleft Palate-Craniofacial Journal</i> , 2020, 57, 499-505.	0.5	3
78	The variable manifestations of disease in pyruvate kinase deficiency and their management. <i>Haematologica</i> , 2020, 105, 2229-2239.	1.7	30
79	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 9-18.	2.5	56
80	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506.	0.5	46
81	Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. <i>Drugs of Today</i> , 2020, 56, 439.	0.7	10
82	Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature. <i>Blood</i> , 2020, 136, 45-46.	0.6	1
83	Characteristics of Children and Adults Treated with Rituximab for Immune Thrombocytopenia (ITP). <i>Blood</i> , 2020, 136, 38-39.	0.6	0
84	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2020, 136, 30-32.	0.6	3
85	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020, 136, 14-14.	0.6	0
86	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
87	<p>Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 175-186.	1.0	19
88	Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 256.	1.2	25
89	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. <i>British Journal of Haematology</i> , 2019, 187, e61-e64.	1.2	6
90	<p>Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease</p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 313-321.	0.7	38

#	ARTICLE	IF	CITATIONS
91	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984173.	1.1	65
92	Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. <i>Chest</i> , 2019, 155, 1226-1233.	0.4	14
93	Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 368-368.	1.1	12
94	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. <i>Annals of Internal Medicine</i> , 2019, 170, 904.	2.0	9
95	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Blood Advances</i> , 2019, 3, 3770-3779.	2.5	58
96	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. <i>Blood Advances</i> , 2019, 3, 3515-3521.	2.5	24
97	Thrombophilia evaluation in pulmonary embolism. <i>Current Opinion in Cardiology</i> , 2019, 34, 603-609.	0.8	9
98	Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. <i>Journal of Internal Medicine</i> , 2019, 285, 223-231.	2.7	48
99	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. <i>Annals of Hematology</i> , 2019, 98, 581-588.	0.8	34
100	Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. <i>British Journal of Anaesthesia</i> , 2019, 122, 19-31.	1.5	73
101	Optimal anticoagulant treatment of cancer-associated venous thromboembolism remains unclear. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 115-116.	1.7	1
102	Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the <i>PRF1A91V</i> gene polymorphism. <i>Journal of Medical Genetics</i> , 2019, 56, 39-42.	1.5	25
103	Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 71-79.	0.9	9
104	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. <i>Blood</i> , 2019, 134, 1060-1060.	0.6	0
105	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. <i>Blood</i> , 2019, 134, 2175-2175.	0.6	0
106	Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. <i>American Journal of Hematology</i> , 2018, 93, E156-E158.	2.0	8
107	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. <i>Haematologica</i> , 2018, 103, e169-e172.	1.7	51
108	Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 81-83.	1.0	13

#	ARTICLE	IF	CITATIONS
109	Hemophagocytic Lymphohistiocytosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 27-49.	9.6	299
110	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. <i>Haematologica</i> , 2018, 103, e492-e495.	1.7	6
111	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. <i>American Journal of Hematology</i> , 2018, 93, 1501-1508.	2.0	55
112	Romiplostim for the management of perioperative thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 182, 106-113.	1.2	37
113	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. <i>Haematologica</i> , 2018, 103, 1433-1443.	1.7	123
114	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 183, 168-168.	1.2	26
115	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2673-2677.	1.1	24
116	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. <i>Cancers</i> , 2018, 10, 271.	1.7	33
117	Shifting landscape of hemophilia therapy: Implications for current clinical laboratory coagulation assays. <i>American Journal of Hematology</i> , 2018, 93, 1082-1090.	2.0	19
118	Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease. <i>Drugs of Today</i> , 2018, 54, 647.	0.7	13
119	Anticoagulation and Enzalutamide: Caution Over Convenience. <i>Journal of Oncology Practice</i> , 2017, 13, 728-729.	2.5	4
120	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. <i>Blood</i> , 2016, 128, 3748-3748.	0.6	2